{"id":9581,"date":"2020-06-15T18:39:51","date_gmt":"2020-06-15T13:09:51","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=9581"},"modified":"2025-05-08T15:37:41","modified_gmt":"2025-05-08T10:07:41","slug":"diabetic-peripheral-neuropathy-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/diabetic-peripheral-neuropathy-market","title":{"rendered":"How are Diabetic Peripheral Neuropathy medications changing the DPN market scenario?"},"content":{"rendered":"\n

Diabetic Peripheral Neuropathy Market is anticipated to grow with a CAGR of 12% for the study period of 2017-2030<\/em><\/strong><\/h3>\n\n\n\n

Diabetic Peripheral Neuropathy (DPN)<\/strong><\/a> or Distal Symmetric Polyneuropathy (DSPN) is peripheral nerve dysfunction and damage in diabetic patients. It is a chiefly sensory neuropathy with autonomic nervous system involvement, although there are often motor features with advancing disease.   <\/p>\n\n\n\n

Diabetic Peripheral Neuropathy is the most common complication of both Type 1 and 2 diabetes <\/a>and occurs in more than half of affected individuals. <\/p>\n\n\n\n

It develops in up to 50% of all people with diabetes and is one of the main risk factors that is contributing to foot ulceration and eventual amputation. The disease has a higher morbidity rate; the amputations have a staggering societal and economic burden. <\/p>\n\n\n\n

Diabetic Peripheral Neuropathy Market Scenario<\/strong><\/h2>\n\n\n\n

According to DelveInsight, the total diagnosed prevalent population of Diabetic Peripheral Neuropathy <\/strong><\/a>in 7 Major Markets was 25,332,829 cases in 2017.<\/p>\n\n\n\n

Majority of symptoms in Diabetic Peripheral Neuropathy are mainly related to a pain condition. The market currently is also pain focused, and all the current therapies, as well as emerging therapies, are for the treatment of painful diabetic peripheral neuropathy. It has been seen that near about 30% of the patients with DPN suffer from pain. To overcome pain, Gene therapy has been developed for DPN pain management. <\/p>\n\n\n\n

The Diabetic Peripheral Neuropathy medications fall into categories like – Antidepressants, Anticonvulsants, Topical Agents and Opioids<\/a>. <\/p>\n\n\n\n

Antidepressants are further bifurcated into Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), and Tricyclic Antidepressants (TCA) group. The medications can be chosen according to patient comorbidities, side effects, drug interaction, and cost.<\/p>\n\n\n\n

The FDA and EMA had currently approved three treatments for pain associated with DPN are Pregabalin, Duloxetine, and Extended-Release Tapentadol. However, it is astonishing to witness that no treatments have been approved for the prevention or reversal of DPN.<\/p>\n\n\n\n

The American Diabetes Association (ADA) recommends Pregabalin and Gabapentin as options from the anticonvulsants group, Duloxetine, and Venlafaxine from the serotonin-norepinephrine reuptake inhibitor group, and finally Nortriptyline and Desipramine from the tricyclic antidepressants group. <\/p>\n\n\n\n

Diabetic Peripheral Neuropathy market<\/a><\/strong> has a diverse pipeline with a plethora of promising therapies. Of the emerging therapies, the most anticipated product for launch is VM202 Besides this; other products are VM202 (Helixmith), NYX-2925 (Aptinyx), WST-057 (4% pirenzepine) (WinSanTor, Inc.), Ricolinostat (Regenacy Pharmaceuticals), NRD.E1 (Novaremed Ltd.), Cebranopadol (Gr\u00fcnenthal GmbH), GRC 17356 (Glenmark Pharmaceuticals), and others are also expected to enter the market by 2030 as effective therapies. <\/p>\n\n\n\n

The prevalence of DPN occurs in both Type 1 and Type 2 Diabetes\u2019 patients, so it leads to a bigger room for new treatments. The therapies that are currently available are associated with adverse side effects, hence provide scope for new drug development with a better safety profile. <\/p>\n\n\n\n

Conclusively, Diabetic Peripheral Neuropathy Market<\/a><\/strong> will increase due to the increasing global burden of diabetes, which is driving the prevalence of diabetic neuropathy, advancement in early diagnosis as well as the launch of the promising therapies. <\/p>\n","protected":false},"excerpt":{"rendered":"

Diabetic Peripheral Neuropathy Market is anticipated to grow with a CAGR of 12% for the study period of 2017-2030 Diabetic Peripheral Neuropathy (DPN) or Distal Symmetric Polyneuropathy (DSPN) is peripheral nerve dysfunction and damage in diabetic patients. It is a chiefly sensory neuropathy with autonomic nervous system involvement, although there are often motor features with […]<\/p>\n","protected":false},"author":1,"featured_media":9590,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17,17434],"tags":[18459,18457,18465,15341,15342,18453,18452,18468,18467,18466,18455,317,18464,18463,18456,18462,18461,18454,18460,18458],"industry":[17225],"therapeutic_areas":[17245],"class_list":["post-9581","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-facts-and-figures","tag-4-pirenzepine","tag-aptinyx","tag-cebranopadol","tag-diabetic-peripheral-neuropathy","tag-diabetic-peripheral-neuropathy-market","tag-diabetic-peripheral-neuropathy-market-scenario","tag-distal-symmetric-polyneuropathy","tag-glenmark-pharmaceuticals","tag-grc-17356","tag-grunenthal-gmbh","tag-helixmith","tag-inc","tag-novaremed-ltd","tag-nrd-e1","tag-nyx-2925","tag-regenacy-pharmaceuticals","tag-ricolinostat","tag-vm-202","tag-winsantor","tag-wst-057","industry-pharmaceutical","therapeutic_areas-neurology"],"acf":[],"yoast_head":"\nDiabetic Peripheral Neuropathy Market | Delveinsight Business Research<\/title>\n<meta name=\"description\" content=\"Diabetic Peripheral Neuropathy Market is anticipated to grow with a CAGR of 12% for the study period of 2017-2030. The total diagnosed prevalent population.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/diabetic-peripheral-neuropathy-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Diabetic Peripheral Neuropathy Market | Delveinsight Business Research\" \/>\n<meta property=\"og:description\" content=\"Diabetic Peripheral Neuropathy Market is anticipated to grow with a CAGR of 12% for the study period of 2017-2030. The total diagnosed prevalent population.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/diabetic-peripheral-neuropathy-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-15T13:09:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-08T10:07:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/15190428\/Diabetic-Peripheral-Neuropathy.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Diabetic Peripheral Neuropathy Market | Delveinsight Business Research","description":"Diabetic Peripheral Neuropathy Market is anticipated to grow with a CAGR of 12% for the study period of 2017-2030. The total diagnosed prevalent population.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/diabetic-peripheral-neuropathy-market","og_locale":"en_US","og_type":"article","og_title":"Diabetic Peripheral Neuropathy Market | Delveinsight Business Research","og_description":"Diabetic Peripheral Neuropathy Market is anticipated to grow with a CAGR of 12% for the study period of 2017-2030. The total diagnosed prevalent population.","og_url":"https:\/\/www.delveinsight.com\/blog\/diabetic-peripheral-neuropathy-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-06-15T13:09:51+00:00","article_modified_time":"2025-05-08T10:07:41+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/15190428\/Diabetic-Peripheral-Neuropathy.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/diabetic-peripheral-neuropathy-market","url":"https:\/\/www.delveinsight.com\/blog\/diabetic-peripheral-neuropathy-market","name":"Diabetic Peripheral Neuropathy Market | Delveinsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/diabetic-peripheral-neuropathy-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/diabetic-peripheral-neuropathy-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/15190428\/Diabetic-Peripheral-Neuropathy.jpg","datePublished":"2020-06-15T13:09:51+00:00","dateModified":"2025-05-08T10:07:41+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Diabetic Peripheral Neuropathy Market is anticipated to grow with a CAGR of 12% for the study period of 2017-2030. The total diagnosed prevalent population.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/diabetic-peripheral-neuropathy-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/diabetic-peripheral-neuropathy-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/15190428\/Diabetic-Peripheral-Neuropathy.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/15190428\/Diabetic-Peripheral-Neuropathy.jpg","width":772,"height":482,"caption":"Diabetic-Peripheral-Neuropathy"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/15190428\/Diabetic-Peripheral-Neuropathy-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Facts and Figures<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>","<span class=\"advgb-post-tax-term\">Facts and Figures<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">4% Pirenzepine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Aptinyx<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Cebranopadol<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Diabetic Peripheral Neuropathy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Diabetic Peripheral Neuropathy Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Diabetic Peripheral Neuropathy Market Scenario<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Distal Symmetric Polyneuropathy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Glenmark Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">GRC 17356<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Gr\u00fcnenthal Gmbh<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Helixmith<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Inc.<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Novaremed Ltd.<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">NRD.E1<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">NYX-2925<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Regenacy Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Ricolinostat<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">VM 202<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Winsantor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">WST-057<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">4% Pirenzepine<\/span>","<span class=\"advgb-post-tax-term\">Aptinyx<\/span>","<span class=\"advgb-post-tax-term\">Cebranopadol<\/span>","<span class=\"advgb-post-tax-term\">Diabetic Peripheral Neuropathy<\/span>","<span class=\"advgb-post-tax-term\">Diabetic Peripheral Neuropathy Market<\/span>","<span class=\"advgb-post-tax-term\">Diabetic Peripheral Neuropathy Market Scenario<\/span>","<span class=\"advgb-post-tax-term\">Distal Symmetric Polyneuropathy<\/span>","<span class=\"advgb-post-tax-term\">Glenmark Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">GRC 17356<\/span>","<span class=\"advgb-post-tax-term\">Gr\u00fcnenthal Gmbh<\/span>","<span class=\"advgb-post-tax-term\">Helixmith<\/span>","<span class=\"advgb-post-tax-term\">Inc.<\/span>","<span class=\"advgb-post-tax-term\">Novaremed Ltd.<\/span>","<span class=\"advgb-post-tax-term\">NRD.E1<\/span>","<span class=\"advgb-post-tax-term\">NYX-2925<\/span>","<span class=\"advgb-post-tax-term\">Regenacy Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Ricolinostat<\/span>","<span class=\"advgb-post-tax-term\">VM 202<\/span>","<span class=\"advgb-post-tax-term\">Winsantor<\/span>","<span class=\"advgb-post-tax-term\">WST-057<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Jun 15, 2020","modified":"Updated on May 8, 2025"},"absolute_dates_time":{"created":"Posted on Jun 15, 2020 6:39 pm","modified":"Updated on May 8, 2025 3:37 pm"},"featured_img_caption":"Diabetic-Peripheral-Neuropathy","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=9581"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9581\/revisions"}],"predecessor-version":[{"id":31990,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9581\/revisions\/31990"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/9590"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=9581"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=9581"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=9581"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=9581"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=9581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}